Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Infection, Genetics and Evolution

Volumn 46, Issue , 2016, Pages 286-291

  Han, Ying Shan ^a   Mesplède, Thibault ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistance; HIV subtypes; Integrase inhibitors

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE INHIBITOR; RALTEGRAVIR; VIRUS RNA; FUSED HETEROCYCLIC RINGS; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP M; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP N; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP O; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP P; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE F; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; DRUG EFFECTS; GENETICS; VIROLOGY;

DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; QUINOLONES; RALTEGRAVIR POTASSIUM;

EID: 84999028775     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2016.06.047     Document Type: Article

References (58)

1. Abram, M.E., Hluhanich, R.M., Goodman, D.D., Andreatta, K.N., Margot, N.A., Ye, L., Niedziela-Majka, A., Barnes, T.L., Novikov, N., Chen, X., Svarovskaia, E.S., McColl, D.J., White, K.L., Miller, M.D., Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 57 (2013), 2654–2663.
2. Akil, B., Blick, G., Hagins, D.P., Ramgopal, M.N., Richmond, G.J., Samuel, R.M., Givens, N., Vavro, C., Song, I.H., Wynne, B., Ait-Khaled, M., Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir. Ther. 20 (2015), 343–348.
3. Alessandri-Gradt, E., Collin, G., et al. HIV-1 Non Group M Phenotypic Susceptibility to Integrase Inhibitors (Dolutegravir, Elvitegravir and Raltegravir). XXV International HIV Drug Resistance Workshop February 20–21, 2016. 2016, ABSTRACT 50, Boston, MA, USA.
4. Avi, R., Huik, K., Sadam, M., Karki, T., Krispin, T., Ainsalu, K., Paap, P., Schmidt, J., Nikitina, N., Lutsar, I., Characterization of integrase region polymorphisms in HIV type 1 CRF06_cpx viruses in treatment-naive patients in Estonia. AIDS Res. Hum. Retrovir. 26 (2010), 1109–1113.
5. Bar-Magen, T., Donahue, D.A., McDonough, E.I., Kuhl, B.D., Faltenbacher, V.H., Xu, H., Michaud, V., Sloan, R.D., Wainberg, M.A., HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 24 (2010), 2171–2179.
6. Bessong, P.O., Nwobegahay, J., Genetic analysis of HIV-1 integrase sequences from treatment naive individuals in northeastern South Africa. Int. J. Mol. Sci. 14 (2013), 5013–5024.
7. Boyd, S.D., Maldarelli, F., Sereti, I., Ouedraogo, G.L., Rehm, C.A., Boltz, V., Shoemaker, D., Pau, A.K., Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir. Ther. 16 (2011), 257–261.
8. Brenner, B.G., Lowe, M., Moisi, D., Hardy, I., Gagnon, S., Charest, H., Baril, J.G., Wainberg, M.A., Roger, M., Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J. Med. Virol. 83 (2011), 751–759.
9. Buonaguro, L., Tornesello, M.L., Buonaguro, F.M., Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81 (2007), 10209–10219.
10. Cahn, P., Pozniak, A.L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J.F., Richmond, G., Buendia, C.B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C.B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., Griffith, S., Min, S., Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382 (2013), 700–708.
11. Canducci, F., Ceresola, E.R., Boeri, E., Spagnuolo, V., Cossarini, F., Castagna, A., Lazzarin, A., Clementi, M., Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J. Infect. Dis. 204 (2011), 1811–1815.
12. Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G., Yeo, J.M., Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J. Infect. Dis. 210 (2014), 354–362.
13. Ceccherini-Silberstein, F., Van Baelen, K., Armenia, D., Trignetti, M., Rondelez, E., Fabeni, L., Scopelliti, F., Pollicita, M., Van Wesenbeeck, L., Van Eygen, V., Dori, L., Sarmati, L., Aquaro, S., Palamara, G., Andreoni, M., Stuyver, L.J., Perno, C.F., Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob. Agents Chemother. 54 (2010), 3938–3948.
14. Charpentier, C., Larrouy, L., Collin, G., Damond, F., Matheron, S., Chene, G., Nie, T., Schinazi, R., Brun-Vezinet, F., Descamps, D., In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 24 (2010), 2753–2755.
15. Cossarini, F., Boeri, E., Canducci, F., Salpietro, S., Bigoloni, A., Galli, L., Spagnuolo, V., Castagna, A., Clementi, M., Lazzarin, A., Gianotti, N., Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 56 (2011), e51–e54.
16. Depatureaux, A., Leoz, M., Le Moal, G., Pathe, J.P., Pavie, J., Batisse, D., Daneluzzi, V., Genet, P., Gerard, L., Lascaux-Cametz, A.S., Lambolez, T., Chennebault, J.M., Plantier, J.C., Raltegravir-based regimens are effective in HIV-1 group O-infected patients. J. Acquir. Immune Defic. Syndr. 61 (2012), e1–e3.
17. Depatureaux, A., Mesplede, T., Quashie, P., Oliveira, M., Moisi, D., Brenner, B., Wainberg, M., HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. J. Int. AIDS Soc., 17, 2014, 19738.
18. Depatureaux, A., Mesplede, T., Quashie, P., Oliveira, M., Moisi, D., Plantier, J.C., Brenner, B., Wainberg, M.A., HIV-1 group O resistance against integrase inhibitors. J. Acquir. Immune Defic. Syndr. 70 (2015), 9–15.
19. Eron, J.J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., Fujiwara, T., Huang, J., Min, S., Vavro, C., Yeo, J., Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J. Infect. Dis. 207 (2013), 740–748.
20. Fourati, S., Charpentier, C., Amiel, C., Morand-Joubert, L., Reigadas, S., Trabaud, M.A., Delaugerre, C., Nicot, F., Rodallec, A., Maillard, A., Mirand, A., Jeulin, H., Montes, B., Barin, F., Bettinger, D., Le Guillou-Guillemette, H., Vallet, S., Signori-Schmuck, A., Descamps, D., Calvez, V., Flandre, P., Marcelin, A.G., Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J. Antimicrob. Chemother. 70 (2015), 1507–1512.
21. Garrido, C., Soriano, V., Geretti, A.M., Zahonero, N., Garcia, S., Booth, C., Gutierrez, F., Viciana, I., de Mendoza, C., Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients–impact of HIV subtypes and prior raltegravir experience. Antivir. Res. 90 (2011), 164–167.
22. Geretti, A.M., Armenia, D., Ceccherini-Silberstein, F., Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr. Opin. Infect. Dis. 25 (2012), 677–686.
23. Grobler, J.A., Hazuda, D.J., Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr. Opin. Virol. 8c (2014), 98–103.
24. Hightower, K.E., Wang, R., Deanda, F., Johns, B.A., Weaver, K., Shen, Y., Tomberlin, G.H., Carter, H.L. 3rd, Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., Underwood, M.R., Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55 (2011), 4552–4559.
25. Hurt, C.B., Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir. Ther. 16 (2011), 137–140.
26. Hurt, C.B., Sebastian, J., Hicks, C.B., Eron, J.J., Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin. Infect. Dis. 58 (2014), 423–431.
27. Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K.W., Ferris, R., Foster, S.A., Hazen, R.J., Miki, S., Suyama-Kagitani, A., Kawauchi-Miki, S., Taishi, T., Kawasuji, T., Johns, B.A., Underwood, M.R., Garvey, E.P., Sato, A., Fujiwara, T., In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55 (2011), 813–821.
28. Lataillade, M., Chiarella, J., Kozal, M.J., Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12 (2007), 563–570.
29. Llacer Delicado, T., Torrecilla, E., Holguin, A., Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals. J. Antimicrob. Chemother. 71 (2016), 362–366.
30. Loizidou, E.Z., Kousiappa, I., Zeinalipour-Yazdi, C.D., Van de Vijver, D.A., Kostrikis, L.G., Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses. Biochemistry 48 (2009), 4–6.
31. Maiga, A.I., Malet, I., Soulie, C., Derache, A., Koita, V., Amellal, B., Tchertanov, L., Delelis, O., Morand-Joubert, L., Mouscadet, J.F., Murphy, R., Cisse, M., Katlama, C., Calvez, V., Marcelin, A.G., Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir. Ther. 14 (2009), 123–129.
32. Malet, I., Soulie, C., Tchertanov, L., Derache, A., Amellal, B., Traore, O., Simon, A., Katlama, C., Mouscadet, J.F., Calvez, V., Marcelin, A.G., Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J. Med. Virol. 80 (2008), 754–761.
33. Malet, I., Fourati, S., Charpentier, C., Morand-Joubert, L., Armenia, D., Wirden, M., Sayon, S., Van Houtte, M., Ceccherini-Silberstein, F., Brun-Vezinet, F., Perno, C.F., Descamps, D., Capt, A., Calvez, V., Marcelin, A.G., The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J. Antimicrob. Chemother. 66 (2011), 2827–2830.
34. Mesplede, T., Wainberg, M.A., Is resistance to dolutegravir possible when this drug is used in first-line therapy?. Viruses 6 (2014), 3377–3385.
35. Mesplede, T., Quashie, P.K., Wainberg, M.A., Resistance to HIV integrase inhibitors. Curr. Opin. HIV AIDS 7 (2012), 401–408.
36. Mesplede, T., Quashie, P.K., Osman, N., Han, Y., Singhroy, D.N., Lie, Y., Petropoulos, C.J., Huang, W., Wainberg, M.A., Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology, 10, 2013, 22.
37. Mphahlele, M., Giacobbi, N., Hewer, R., Travers, S.A.A., Mosebi, S., Steegen, K., Venter, F., Carmona, S., Stevens, W.S., Sluis-Cremer, N., Papathanasopoulos, M.A., In Vitro Selection of HIV-1 Subtype C Resistant to Integrase Strand Transfer Inhibitors. XXV International HIV Drug Resistance Workshop February 20–21, 2016. 7, 2016 (Boston).
38. Mulu, A., Maier, M., Liebert, U.G., Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates. J. Transl. Med., 13, 2015, 377.
39. Myers, R.E., Pillay, D., Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J. Virol. 82 (2008), 9228–9235.
40. Nguyen, H.L., Ruxrungtham, K., Delaugerre, C., Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. Intervirology 55 (2012), 287–295.
41. Nouhin, J., Donchai, T., Hoang, K.T., Ken, S., Kamkorn, J., Tran, T., Ayouba, A., Peeters, M., Chaix, M.L., Lien, T.X., Nerrienet, E., Ngo-Giang-Huong, N., Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. Infect. Genet. Evol. 11 (2011), 38–43.
42. Osman, N., Mesplede, T., Quashie, P.K., Oliveira, M., Zanichelli, V., Wainberg, M.A., Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J. Antimicrob. Chemother. 70 (2015), 2810–2815.
43. Park, T.E., Mohamed, A., Kalabalik, J., Sharma, R., Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev. Anti-Infect. Ther. 13 (2015), 1195–1212.
44. Passaes, C.B., Guimaraes, M.L., Fernandez, S.L., Lorete Rdos, S., Teixeira, S.L., Fernandez, J.C., Morgado, M.G., Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J. Acquir. Immune Defic. Syndr. 51 (2009), 7–12.
45. Phuphuakrat, A., Pasomsub, E., Kiertiburanakul, S., Chantratita, W., Sungkanuparph, S., HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates. AIDS Res. Hum. Retrovir. 28 (2012), 937–943.
46. Quashie, P.K., Mesplede, T., Wainberg, M.A., Evolution of HIV integrase resistance mutations. Curr. Opin. Infect. Dis. 26 (2013), 43–49.
47. Quashie, P.K., Oliviera, M., Veres, T., Osman, N., Han, Y.S., Hassounah, S., Lie, Y., Huang, W., Mesplede, T., Wainberg, M.A., Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J. Virol. 89 (2015), 3163–3175.
48. Santoro, M.M., Perno, C.F., HIV-1 genetic variability and clinical implications. ISRN Microbiol., 2013, 2013, 481314.
49. Sierra, S., Lubke, N., Walter, H., Schulter, E., Reuter, S., Fatkenheuer, G., Bickel, M., da Silva, H., Kaiser, R., Esser, S., The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes. Med. Microbiol. Immunol. 200 (2011), 225–232.
50. Tebit, D.M., Arts, E.J., Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect. Dis. 11 (2011), 45–56.
51. Tebit, D.M., Patel, H., Ratcliffe, A., Alessandri, E., Liu, J., Carpenter, C., Plantier, J.C., Arts, E., HIV-1 group O genotypes and phenotypes: relationship to fitness and susceptibility to antiretroviral drugs. AIDS Res. Hum. Retrovir., 2016, 10.1089/aid.2015.0318.
52. Turriziani, O., Montagna, C., Falasca, F., Bucci, M., Russo, G., Lichtner, M., Sobze, M.S., Vullo, V., Pistello, M., Antonelli, G., Short communication: analysis of the integrase gene from HIV type 1-positive patients living in a rural area of West Cameroon. AIDS Res. Hum. Retrovir. 28 (2012), 1729–1733.
53. Underwood, M.R., Vavro, C.L., Haney, R., Horton, J., Epidemiology of dolutegravir (DTG) resistance in ~ 700 raltegravir-resistant isolates. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4–8, 2013, 2013, Abstract 85, Toronto, Canada.
54. Underwood, M.R., DeAnda, F., et al. Resistance post week 48 in ART-experienced, integrase inhibitor-naive subjects with dolutegravir (DTG) vs. raltegravir (RAL) in SAILING (ING111762). 13th European HIV & Hepatitis Workshop, June 3–5, 2015, 2015 (Barcelona, Spain).
55. Van Baelen, K., Rondelez, E., Van Eygen, V., Arien, K., Clynhens, M., Van den Zegel, P., Winters, B., Stuyver, L.J., A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J. Virol. Methods 161 (2009), 231–239.
56. Vavro, C., et al. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, Canada, July 19-22, 2015. 2015.
57. Wainberg, M.A., Han, Y.S., Will drug resistance against dolutegravir in initial therapy ever occur?. Front. Pharmacol., 6, 2015, 90.
58. Wainberg, M.A., Mesplede, T., Raffi, F., What if HIV were unable to develop resistance against a new therapeutic agent?. BMC Med., 11, 2013, 249.